INMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
INMED PHARMACEUTICALS INC. (INM) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $4.14 per share as of 2025-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2026-09-09
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $4.14.
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $4.14.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $4.14.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $7.40; Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price as first filed $0.37.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price as first filed |
|---|---|---|
| 2025-06-30 | $4.14 S-4/A · filed 2026-09-09 | |
| 2025-03-31 | $4.14 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $4.14 10-Q · filed 2025-02-12 | |
| 2024-06-30 | $7.40 S-4 · filed 2026-07-02 | $0.37 10-K · filed 2024-09-30 |
| 2024-03-31 | $0.37 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $7.40 10-Q · filed 2025-02-12 | $0.37 10-Q · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |